Bright Minds Biosciences (DRUG) Stock Statistics & Valuation Metrics

Bright Minds Biosciences has a market cap or net worth of $698.77M. The enterprise value is $473.17.

Bright Minds Biosciences has 9,864,061 shares outstanding. The number of shares has decreased by -2.65% in one year.

Bright Minds Biosciences’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -16.96%.

The current PE Ratio of Bright Minds Biosciences is ―. Bright Minds Biosciences’s PEG ratio is -0.27.

In the last 12 months, Bright Minds Biosciences had revenue of 0.00 and earned -12.23M in profits. Earnings per share was -1.78.

In the last 12 months, operating cash flow was -25.00M and capital expenditures -4.00, giving a free cash flow of -25.00M billion.

Bright Minds Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Bright Minds Biosciences upcoming earnings date is Dec 17, 2026, Before Open (Confirmed).

Bright Minds Biosciences as a current ratio of 36.10, with Debt / Equity ratio of 0.02%

In the past 12 months, Bright Minds Biosciences has paid 0.00 in taxes.

Bright Minds Biosciences EV to EBITDA ratio is -40.98, with an EV/FCF ratio of -57.29.

Bright Minds Biosciences has $308.33M in cash and marketable securities with $65.70K in debt, giving a net cash position of $308.27M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Bright Minds Biosciences is $145.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy